Represents the amount of accrued milestone payment. Accrued Milestone Payment Accrued milestone payment Adjustment For Exchange Rate Differences Loss Gain On Cash Balances Exchange rate differences gain on cash balances Represent the amount of amortization of discount on marketable securities. Amortization of discount on marketable securities Amortization Of Discount On Marketable Securities Clinical Amount Of Expense For Research And Development Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Clinical R&D expenses Commercial License Agreement [Member] Commercial License Agreement [Member] Employees Directors And Non Employees [Member] Information about the employees, directors and non-employees. Financial Income (Expense), Net. Financial income, net Financial Income Expense Net Financial and other income, net Financial and other income, net Financial and other income, net General And Administrative Expenses [Member] General and Administrative Expense Government and Other Grants [Axis] Government and Other Grants [Axis] Government And Other Grants [Domain] Government And Other Grants [Line Items] Government and Other Grants [Line Items] Government and Other Grants [Member] Government and Other Grants [Member] Government And Other Grants [Table] Government and Other Grants [Table] Increase Decrease In Deferred Revenues Represent the amount of deferred revenues Decrease in deferred revenues Increase Decrease In Interest Receivables And Exchange Differences On Long Term Bank Deposits Represents amount for increase decrease in interest receivables and exchange differences on long term bank deposits. Increase in interest receivables and exchange differences on restricted long-term bank deposits Increase Decrease In Interest Receivables And Exchange Differences On Short Term Bank Deposits Represents amount for increase decrease in interest receivables and exchange differences on short term bank deposits. Increase in interest receivables and exchange differences on short-term bank deposits Increase in interest receivables and exchange differences on short-term bank deposits Decrease in operating lease right of use asset. Decrease in operating lease right of use asset Increase Decrease In Operating Lease Right Of Use Asset Long term deferred participation in R&D expenses. Long Term Deferred Participationin Research And Development Expenses Deferred revenues Maximum Amount To Be Repaid As Percentage It represents as a maximum amount to be repaid as percentage. Maximum amount to be repaid as percentage Maximum authorized proceeds from issuance of common stock. Maximum Authorized Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock Maximum Royalty Repaid As Percentage Of Grant Received Maximum royalty repaid as percentage of grant received Maximum royalty repaid as percentage of grant received Milestone Payment Receivable Amount of milestone payment receivables. Milestone payment Numerator: Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block] Recently issued accounting pronouncements Non Refundable Upfront Payment Amount of non-refundable upfront payment. Non-refundable upfront payment Number of warrants exercised. Number Of Warrants Exercised Warrants exercised, shares Other Segment Expenses Other segment expenses. Other segment expenses Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor. Participation Rights Percentage of closing price. Percentage of closing price Percentage Of Expected From Upfront Payment Amount Paid Percentage of expected from upfront payment amount paid. Percentage of expected from upfront payment amount paid Percentage of royalties on net sales. Percentage of royalties on net sales Information about the plan 2010 member. Plan 2010 [Member] Preclinical Amount Of Expense For Research And Development Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Preclinical R&D expenses The amount of purchase property and equipment as non cash transaction. Purchase of property and equipment Purchase Of Property And Equipment As Non Cash Transaction Purchase of property and equipment Receivables on account of shares. Receivables On Account Of Shares Receivables on account of shares Recently Issued Accounting Pronouncements [Policy Text Block] Accounting policy for recently issued accounting pronouncements. Registered direct offering [Member] Registered direct offering [Member] Related Party Balances And Transactions Abstract Relative fair value of deferred participation. Relative Fair Value Of Deferred Participation Relative fair value of deferred participation Research And Development Activities Remaining Performance Obligation Amount Amount of transaction price allocated to performance obligation recognized as research and development activities. Remaining performance obligations allocated to research and development activities Research And Development Activities Remaining Performance Obligation Percentage Percentage of remaining performance obligation to total remaining performance obligation recognized as research and development activities. Percentage of remaining performance obligations allocated to research and development activities Addition Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements. Research And Development Arrangement Additional Payments Receivable Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements. Research And Development Arrangement Payments Receivable Potential milestone compensation Potential milestone compensation company is now eligible for. Research And Development Arrangement Payments Receivable On Remaining Program Potential milestone compensation company is now eligible for Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements. Research And Development Arrangement Preclinical Payments Receivable Preclinical milestone compensation Research And Development Expenses [Member] Research and development expenses milestone payment. Research And Development Expenses Milestone Payment Research and development expenses milestone payment Represents Research and development grant one member. Research And Development Grant One [Member] Research And Development Grant One [Member] Retainer fee per month. Retainer Fee Retainer fee Revenue [Abstract] Revenue Disclosure [Text Block] The entire disclosure for revenue. REVENUES Revenue [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Revenue [Table] The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued. Royalty Contingent Obligations Contingent royalty obligations Royalty Percentage Based On Future Revenues Royalty percentage based on future revenues Royalty percentage based on future revenues Information about the Sales Agreement with Leerink Partner LLC member. Sales Agreement With Leerink Partner Llc [Member] Sales Agreement With Leerink Partner LLC [Member] Schedule Of Revenue [Table Text Block] Tabular disclosure of revenue. Schedule of revenue Segment Reporting Geographic Area [Axis] Segment Reporting Geographic Area [Axis] Segment Reporting Geographic Area [Domain] Selling And Marketing Expenses [Member] Represent the member of Selling and Marketing Expense Marketing and business development expenses [Member] Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason. Severance Pay Fund Non Current Severance pay fund Severance pay, net. Severance Pay Net Decrease in severance pay, net Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Net Settled In Period The number of equity-based payment instruments, excluding stock (or unit) options, that net settled during the reporting period. RSUs net settled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Net Settled In Period Weighted Average Grant Date Fair Value Share based compensation arrangement by share based payment award equity instruments other than options net settled in period weighted average grant date fair value. RSUs net settled Weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract Short term deferred participation in R&D expenses. Short Term Deferred Participation In Research And Development Expenses Deferred revenues Single operating segment. Single Operating Segment [Member] Statement Of Income Location Balance [Domain] Statement Of Income Location Balances [Axis] Statement Of Income Location Balance Statement Of Income Location Balances [Domain] Statement Of Income Location Balance Statement Of Location Income Balance [Axis] Statement Of Location Income Balance [Domain] Stock-based compensation relating to options issued to employees and directors. Stock Based Compensation Relating To Options Issued To Employees And Directors Value Stock-based compensation issued to employees, directors and non-employees APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock Issued During Period Shares Common Stock Issued For Rsus Vesting Represent the number of Stock Issued During Period Shares Common Stock Issued For Rsu Vesting Issuance of shares upon RSU vesting, shares Stock Issued During Period Value Common Stock Issued For Rsu Vesting Represent the amount of Stock Issued During Period Value Common Stock Issued For Rsu Vesting Issuance of shares upon RSU vesting Value of stock issued as a result of the exercise of warrants. Stock Issued During Period Value Warrants Exercised Warrants exercised Represent the Right-of-use asset obtained in exchange for operating lease liability Supplemental Right Of Use Asset And Operating Lease Liability Right-of-use asset obtained in exchange for operating lease liability SVB Leerink LLC and Stifel, Nicolaus & Company [Member] Svb Leerink Llc And Stifel Nicolaus And Company [Member] SVB Leerink LLC and Stifel, Nicolaus & Company [Member] Trade and other payables related parties. Trade And Other Payables Related Parties Trade and other payables Unaudited Interim Consolidated Financial Statements [Abstract] The entire disclosure of unaudited interim consolidated financial statements. Unaudited Interim Consolidated Financial Statements [Text Block] UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Underwriters [Member] Underwriters [Member] Israel [Member] Unites States [Member] United States Amendment Flag Cover [Abstract] Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address Country Entity Address, Postal Zip Code Entity Central Index Key Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Europe [Member] Customer [Axis] Maximum [Member] Minimum [Member] Customer [Domain] Range [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Geographical [Domain] Geographical [Axis] Geographical [Axis] Scenario [Axis] SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounting Policies [Abstract] Trade payables Accounts receivable Accrued Liabilities, Current Accrued expenses Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Accumulated other comprehensive Income (loss) [Member] Additional paid-in capital Additional paid-in capital [Member] Stock-based compensation issued to employees, directors and non-employees Adjustments required to reconcile net loss to net cash used in operating activities: Stock-based compensation expenses Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Securities excluded from the calculations Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Assets Total assets ASSETS Assets, Current Total current assets CURRENT ASSETS: Assets, Fair Value Disclosure [Abstract] Assets: Assets, Noncurrent Total non-current assets NON-CURRENT ASSETS: Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross unrealized losses Debt Securities, Available-for-Sale, Amortized Cost Amortized cost Debt Securities, Available-for-Sale Fair value Award Type [Axis] Award type [Axis] Marketing and business development expenses Marketing and business development expenses Purchase of property and equipment Capital Expenditures Incurred but Not yet Paid Purchase of property and equipment Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Cash, cash equivalents at the end of the period Cash, cash equivalents at the beginning of the period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Decrease in cash, cash equivalents and restricted cash Supplemental disclosure of non-cash investing and financing activities: Exercise price of warrants Warrants purchase to ordinary shares Warrants purchase to ordinary shares remain outstanding COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4) COMMITMENTS AND CONTINGENT LIABILITIES COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES Common Stock, Capital Shares Reserved for Future Issuance Number of shares reserved for issuance Ordinary shares [Member] Ordinary shares, par value per share Ordinary shares, par value Ordinary shares, shares authorized Ordinary shares, shares issued Balance, shares Balance, shares Ordinary shares, shares outstanding Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2026, and December 31, 2025; 94,724,146 and 94,553,191 shares issued and outstanding on June 30, 2026, and December 31, 2025, respectively Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration of credit risks Sales to a single customer exceeding 10% Concentration Risk Type [Domain] Corporate Debt Securities [Member] Governmental bonds [Member] U.S. government bonds [Member] Cost of Revenue Cost of revenues Related parties' expenses amounts charged to research and development expenses Research and development expenses Customer Concentration Risk [Member] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table Text Block] Schedule of available-for-sale marketable securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Schedule of gross unrealized losses and fair values on investments Schedule of unrealized loss on investments Deferred Revenue Deposits Assets, Noncurrent Restricted long-term bank deposit Depreciation Earnings Per Share [Abstract] Basic net loss per share Basic net loss per share Basic loss per ordinary share Earnings Per Share, Diluted Diluted net loss per share Diluted loss per ordinary share Basic and diluted loss per share LOSSES PER SHARE Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Unrecognized compensation cost Period over which compensation expense will be recognized Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized estimated compensation cost Employee Stock Purchase Plan [Member] Share based compensation ESPP Equity investment European Union [Member] Europe Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of fair value measurements Asset Class [Domain] Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Purchase of property and equipment Financial Instrument [Axis] Gain Contingencies, Nature [Axis] Gain (Loss) on Disposition of Property Plant Equipment Gain from property and equipment sales and disposals General and administrative expenses General and administrative expenses Gross Profit Gross profit (loss) Guarantor Obligations, Nature [Axis] Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before taxes on income Income Statement [Abstract] TAXES ON INCOME [Abstract] TAXES ON INCOME Tax expense Tax benefit Income Tax Expense (Benefit) Taxes on income Income tax expenses (tax benefits) Increase in trade receivables Increase (Decrease) in Accounts and Other Receivables Increase in other accounts payable and accrued expenses Decrease in other accounts payable and accrued expenses Increase in trade payables Decrease in trade payables Increase in other accounts receivable and prepaid expenses Increase (Decrease) in Accounts Receivable Increase (Decrease) in Deferred Revenue Deferred revenue Decrease in operating lease liability De